ROIVRoivant Sciences Ltd.
Is it safe?
Nothing alarming, nothing pristine: insiders quiet, heavy debt (CCC), and typical volatility.
Insiders were net sellers (-$59.8M, 90 days to Oct 8, 2026), selling is often routine.
Debt against weak or negative operating profit. A rule of thumb on leverage, not a credit rating.
Moderate price swings, typical volatility. Worst drawdown -79% · now 15% below its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can ROIV take a bad year?
The deepest fall in ROIV's price history on file is −79%; it is 15% below its high today.
Worst drawdown on file · −15% today
- Cash runway
- 4.6 years
Cash runway · burning $208M a quarter at the current rate
- Annualised volatility
- 40%
Annualised volatility · roughly twice as jumpy as the market
Details›
- Cash and short-term investments
- $3.84B
- EBITDA, trailing twelve months
- −$593M
- Operating profit, trailing twelve months
- −$596M
- Annualised volatilitytwo years of daily moves
- 40%
- Worst drawdown on file
- −79%
- Below its 52-week high
- 15%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Biotechnology
Ranks #19 of 196 by RyuScore